Skip to content
n:ews
Back to feed
Health Company signal
Researcher looking through a microscope in a laboratory
Photo: Edward Jenner / Pexels

Genmab Adds Over $10 Billion in Value on Cancer Drug Trial Wins

Genmab shares jumped about 30% on Oct. 28 after a late-stage trial of its drug petosemtamab combined with Keytruda showed a survival benefit in head and neck cancer. The stock has added more than $10 billion in market value this week to trade at a record, following earlier positive trial readouts in ovarian cancer and lymphoma. JPMorgan upgraded the shares to overweight.